Harvard Bioscience, Inc.
HBIO
$7.08
$0.111.58%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 22.73M | 20.76M | 23.74M | 20.59M | 20.45M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 22.73M | 20.76M | 23.74M | 20.59M | 20.45M |
| Cost of Revenue | 10.10M | 8.51M | 9.56M | 8.57M | 8.92M |
| Gross Profit | 12.63M | 12.24M | 14.17M | 12.02M | 11.53M |
| SG&A Expenses | 10.02M | 10.04M | 7.81M | 8.79M | 8.80M |
| Depreciation & Amortization | 820.00K | 820.00K | 850.00K | 855.00K | 1.16M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.39M | 21.69M | 20.41M | 20.35M | 21.07M |
| Operating Income | -660.00K | -939.00K | 3.33M | 245.00K | -619.00K |
| Income Before Tax | -2.90M | -3.31M | -3.20M | -1.13M | -2.25M |
| Income Tax Expenses | 14.00K | 117.00K | -357.00K | 97.00K | 28.00K |
| Earnings from Continuing Operations | -2.91M | -3.42M | -2.85M | -1.23M | -2.28M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.91M | -3.42M | -2.85M | -1.23M | -2.28M |
| EBIT | -660.00K | -939.00K | 3.33M | 245.00K | -619.00K |
| EBITDA | 715.00K | 411.00K | 4.68M | 1.57M | 997.00K |
| EPS Basic | -0.64 | -0.77 | -0.64 | -0.28 | -0.52 |
| Normalized Basic EPS | -0.36 | -0.43 | -0.42 | -0.15 | -0.29 |
| EPS Diluted | -0.64 | -0.77 | -0.64 | -0.30 | -0.52 |
| Normalized Diluted EPS | -0.36 | -0.43 | -0.42 | -0.15 | -0.29 |
| Average Basic Shares Outstanding | 4.53M | 4.47M | 4.46M | 4.46M | 4.43M |
| Average Diluted Shares Outstanding | 4.53M | 4.47M | 4.46M | 4.46M | 4.43M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |